Access Pharmaceuticals Cobraxane Program Displays Significant Advantage Over Commercially-Available Paclitaxel Protein-Bound Particles

Wednesday, May 11, 2011 General News
Email Print This Page Comment
Font : A-A+

Comparative Studies From Company's CobaCyte Tumor-Targeting Technology Program, Cobraxane, Demonstrate Superior Tumor Growth Inhibition

Contact: Company

Contact: Investor Relations

Christine Berni

Donald C. Weinberger/Diana Bittner (media)

Director of Investor Relations

Wolfe Axelrod Weinberger Assoc. LLC

Access Pharmaceuticals, Inc.

(212) 370-4500

(212) 786-6208



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook